| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multidetector Computed Tomography | 2 | 2019 | 147 | 0.730 |
Why?
|
| Meningeal Neoplasms | 3 | 2020 | 473 | 0.670 |
Why?
|
| Radiosurgery | 9 | 2023 | 1383 | 0.660 |
Why?
|
| Brain Edema | 1 | 2018 | 96 | 0.610 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2017 | 33 | 0.580 |
Why?
|
| Brain Neoplasms | 14 | 2023 | 4958 | 0.550 |
Why?
|
| Spinal Neoplasms | 2 | 2019 | 670 | 0.540 |
Why?
|
| Fascia | 2 | 2014 | 55 | 0.530 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2017 | 7894 | 0.530 |
Why?
|
| Neuroimaging | 2 | 2017 | 402 | 0.480 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 908 | 0.450 |
Why?
|
| Skull Neoplasms | 1 | 2012 | 68 | 0.390 |
Why?
|
| Myxoma | 1 | 2012 | 67 | 0.390 |
Why?
|
| Herpes Zoster | 1 | 2011 | 53 | 0.380 |
Why?
|
| Spinal Cord Diseases | 1 | 2011 | 88 | 0.370 |
Why?
|
| Temporal Bone | 1 | 2012 | 109 | 0.370 |
Why?
|
| Neck | 1 | 2012 | 393 | 0.350 |
Why?
|
| Postoperative Complications | 2 | 2019 | 5675 | 0.350 |
Why?
|
| Melanoma | 6 | 2023 | 5594 | 0.340 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 1840 | 0.320 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 2902 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2020 | 10385 | 0.240 |
Why?
|
| Glioblastoma | 4 | 2021 | 1776 | 0.230 |
Why?
|
| Orbit Evisceration | 2 | 2014 | 47 | 0.230 |
Why?
|
| Parathyroid Neoplasms | 2 | 2018 | 189 | 0.230 |
Why?
|
| Adult | 27 | 2020 | 81975 | 0.220 |
Why?
|
| Male | 34 | 2020 | 128374 | 0.200 |
Why?
|
| Four-Dimensional Computed Tomography | 2 | 2020 | 231 | 0.190 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2014 | 551 | 0.190 |
Why?
|
| Aged | 27 | 2020 | 73375 | 0.190 |
Why?
|
| Spinal Diseases | 2 | 2011 | 131 | 0.180 |
Why?
|
| Adenoma | 2 | 2018 | 739 | 0.180 |
Why?
|
| Ipilimumab | 3 | 2023 | 759 | 0.180 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 238 | 0.170 |
Why?
|
| Methotrexate | 2 | 2001 | 1025 | 0.170 |
Why?
|
| Middle Aged | 27 | 2020 | 90334 | 0.160 |
Why?
|
| Humans | 40 | 2023 | 270744 | 0.160 |
Why?
|
| Radiation Injuries | 3 | 2017 | 1470 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2014 | 7784 | 0.150 |
Why?
|
| Trigeminal Neuralgia | 1 | 2018 | 42 | 0.150 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 339 | 0.150 |
Why?
|
| Thyroid Gland | 1 | 2020 | 366 | 0.150 |
Why?
|
| Interferon Inducers | 1 | 1997 | 9 | 0.150 |
Why?
|
| Lateral Ventricles | 1 | 2017 | 25 | 0.140 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2018 | 334 | 0.140 |
Why?
|
| Spine | 1 | 2019 | 312 | 0.140 |
Why?
|
| Spinal Cord Compression | 1 | 2018 | 167 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 4 | 2013 | 4140 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2001 | 1347 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2018 | 824 | 0.140 |
Why?
|
| Bevacizumab | 2 | 2017 | 967 | 0.130 |
Why?
|
| Interferon Type I | 1 | 1997 | 282 | 0.130 |
Why?
|
| Thyroid Neoplasms | 2 | 2020 | 1884 | 0.130 |
Why?
|
| Retrospective Studies | 16 | 2022 | 39827 | 0.130 |
Why?
|
| Female | 29 | 2020 | 148945 | 0.120 |
Why?
|
| Aged, 80 and over | 12 | 2020 | 31006 | 0.120 |
Why?
|
| Orbital Neoplasms | 2 | 2014 | 233 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2017 | 293 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2019 | 1689 | 0.120 |
Why?
|
| RNA, Messenger | 4 | 1997 | 6398 | 0.120 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 12028 | 0.120 |
Why?
|
| Young Adult | 10 | 2020 | 22216 | 0.120 |
Why?
|
| Myocutaneous Flap | 1 | 2014 | 32 | 0.120 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2014 | 76 | 0.120 |
Why?
|
| Radiography | 1 | 2019 | 1986 | 0.120 |
Why?
|
| Skull Base Neoplasms | 1 | 2018 | 339 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 5171 | 0.110 |
Why?
|
| Tumor Burden | 3 | 2017 | 2033 | 0.110 |
Why?
|
| Skin Transplantation | 1 | 2014 | 185 | 0.110 |
Why?
|
| Retropharyngeal Abscess | 1 | 2012 | 11 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 5569 | 0.110 |
Why?
|
| Multimodal Imaging | 2 | 2014 | 550 | 0.110 |
Why?
|
| Dermatofibrosarcoma | 1 | 2013 | 73 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1999 | 1067 | 0.110 |
Why?
|
| Lipoma | 1 | 2012 | 93 | 0.100 |
Why?
|
| Maxillofacial Abnormalities | 1 | 2011 | 13 | 0.100 |
Why?
|
| Circadian Rhythm | 4 | 1997 | 332 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 2344 | 0.100 |
Why?
|
| Cytokines | 3 | 1998 | 2826 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 6192 | 0.100 |
Why?
|
| Erdheim-Chester Disease | 1 | 2011 | 55 | 0.090 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2011 | 84 | 0.090 |
Why?
|
| Methylprednisolone | 1 | 2011 | 198 | 0.090 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2010 | 45 | 0.090 |
Why?
|
| Immunoglobulins | 1 | 2011 | 286 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2021 | 2161 | 0.090 |
Why?
|
| Carcinoma | 2 | 2011 | 2609 | 0.090 |
Why?
|
| Diagnostic Imaging | 2 | 2022 | 1174 | 0.080 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2015 | 796 | 0.080 |
Why?
|
| Vagus Nerve | 1 | 2010 | 70 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 1946 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2012 | 689 | 0.080 |
Why?
|
| Exanthema | 1 | 2011 | 212 | 0.080 |
Why?
|
| ROC Curve | 3 | 2020 | 1250 | 0.080 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2010 | 155 | 0.080 |
Why?
|
| Adolescent | 8 | 2019 | 32735 | 0.080 |
Why?
|
| Brain Stem | 1 | 2010 | 185 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 16669 | 0.080 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 402 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 451 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 1335 | 0.080 |
Why?
|
| Vomiting | 1 | 2010 | 362 | 0.080 |
Why?
|
| Brain Diseases | 1 | 2011 | 412 | 0.080 |
Why?
|
| Surgical Flaps | 1 | 2014 | 887 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2011 | 566 | 0.070 |
Why?
|
| Nausea | 1 | 2010 | 540 | 0.070 |
Why?
|
| Brain | 2 | 2017 | 4212 | 0.070 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 2027 | 0.070 |
Why?
|
| RNA, Viral | 3 | 1998 | 730 | 0.070 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 496 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2012 | 5589 | 0.070 |
Why?
|
| Survival Rate | 5 | 2019 | 12526 | 0.060 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 15210 | 0.060 |
Why?
|
| Radiotherapy, Conformal | 1 | 2010 | 898 | 0.060 |
Why?
|
| Sleep | 3 | 1997 | 446 | 0.060 |
Why?
|
| Biopsy | 1 | 2012 | 3483 | 0.060 |
Why?
|
| Disease Progression | 4 | 2018 | 6855 | 0.060 |
Why?
|
| Combined Modality Therapy | 4 | 2023 | 9039 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2017 | 3557 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2017 | 585 | 0.050 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2010 | 1161 | 0.050 |
Why?
|
| Acute-Phase Reaction | 2 | 1998 | 24 | 0.050 |
Why?
|
| Child | 3 | 2017 | 30538 | 0.050 |
Why?
|
| Sarcoma | 1 | 2011 | 1838 | 0.050 |
Why?
|
| RNA, Double-Stranded | 2 | 1998 | 106 | 0.040 |
Why?
|
| Skin Neoplasms | 2 | 2014 | 4889 | 0.040 |
Why?
|
| Growth Hormone-Releasing Hormone | 2 | 1996 | 17 | 0.040 |
Why?
|
| Radiopharmaceuticals | 2 | 2018 | 1341 | 0.040 |
Why?
|
| Prognosis | 4 | 2022 | 22480 | 0.040 |
Why?
|
| Actuarial Analysis | 1 | 1999 | 170 | 0.040 |
Why?
|
| Logistic Models | 2 | 2020 | 3448 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 2664 | 0.040 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2018 | 125 | 0.040 |
Why?
|
| Breakthrough Pain | 1 | 2018 | 18 | 0.040 |
Why?
|
| Protons | 1 | 2021 | 482 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2023 | 33733 | 0.040 |
Why?
|
| Neck Pain | 1 | 2018 | 41 | 0.040 |
Why?
|
| Orthomyxoviridae Infections | 1 | 1998 | 70 | 0.040 |
Why?
|
| Newcastle disease virus | 1 | 1997 | 7 | 0.040 |
Why?
|
| Pituitary Gland, Anterior | 1 | 1997 | 36 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 727 | 0.040 |
Why?
|
| Sleep, REM | 1 | 1997 | 30 | 0.040 |
Why?
|
| Hyperprolactinemia | 1 | 1997 | 20 | 0.040 |
Why?
|
| Poly I-C | 1 | 1997 | 31 | 0.040 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2018 | 142 | 0.040 |
Why?
|
| Corticosterone | 1 | 1997 | 123 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6255 | 0.030 |
Why?
|
| Brain Chemistry | 1 | 1997 | 166 | 0.030 |
Why?
|
| Tubulin | 1 | 1997 | 202 | 0.030 |
Why?
|
| Remission Induction | 2 | 2001 | 3652 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2018 | 4001 | 0.030 |
Why?
|
| Steroids | 1 | 2018 | 371 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 416 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 7915 | 0.030 |
Why?
|
| Necrosis | 1 | 2017 | 595 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 4829 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2017 | 209 | 0.030 |
Why?
|
| Fixatives | 1 | 1994 | 31 | 0.030 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 1994 | 45 | 0.030 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 1994 | 40 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2012 | 9290 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 3 | 1997 | 3478 | 0.030 |
Why?
|
| Contrast Media | 2 | 2011 | 1499 | 0.030 |
Why?
|
| Hypothalamus | 1 | 1996 | 272 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 1997 | 589 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 1994 | 137 | 0.030 |
Why?
|
| Actins | 1 | 1997 | 602 | 0.030 |
Why?
|
| Positron-Emission Tomography | 2 | 2014 | 2196 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2018 | 1018 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2015 | 251 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2018 | 1042 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 1999 | 3530 | 0.030 |
Why?
|
| Time Factors | 2 | 2017 | 13021 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1189 | 0.030 |
Why?
|
| Lymphoma | 1 | 2001 | 1520 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 1996 | 631 | 0.030 |
Why?
|
| Everolimus | 1 | 2015 | 436 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2015 | 766 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 2271 | 0.020 |
Why?
|
| Rheumatoid Nodule | 1 | 2011 | 6 | 0.020 |
Why?
|
| Hyoid Bone | 1 | 2011 | 8 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1997 | 1585 | 0.020 |
Why?
|
| Triiodobenzoic Acids | 1 | 2011 | 69 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 2015 | 813 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 173 | 0.020 |
Why?
|
| Thoracic Vertebrae | 1 | 2011 | 200 | 0.020 |
Why?
|
| raf Kinases | 1 | 2010 | 80 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 2012 | 322 | 0.020 |
Why?
|
| Corpus Callosum | 1 | 2010 | 127 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2011 | 247 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2010 | 167 | 0.020 |
Why?
|
| Quinazolines | 1 | 2015 | 956 | 0.020 |
Why?
|
| Causality | 1 | 2010 | 176 | 0.020 |
Why?
|
| Sirolimus | 1 | 2014 | 831 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2021 | 13414 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2010 | 188 | 0.020 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 196 | 0.020 |
Why?
|
| Piperidines | 1 | 2015 | 1098 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 14012 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2022 | 9473 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 985 | 0.020 |
Why?
|
| Algorithms | 1 | 2020 | 3900 | 0.020 |
Why?
|
| Valproic Acid | 1 | 2010 | 274 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 4963 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 5070 | 0.020 |
Why?
|
| Niacinamide | 1 | 2010 | 428 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2011 | 382 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2011 | 360 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 470 | 0.020 |
Why?
|
| Risk Factors | 2 | 2019 | 17896 | 0.020 |
Why?
|
| Rats | 4 | 1997 | 6525 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 1468 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1997 | 2212 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 2073 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2014 | 17043 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2010 | 604 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2010 | 600 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 1999 | 5921 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 1267 | 0.020 |
Why?
|
| Palliative Care | 1 | 2018 | 2178 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2010 | 986 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2011 | 1260 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 10260 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2001 | 2319 | 0.020 |
Why?
|
| Animals | 7 | 1998 | 62045 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 4328 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2010 | 1570 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2012 | 2122 | 0.010 |
Why?
|
| Radiometry | 1 | 2010 | 1018 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 5102 | 0.010 |
Why?
|
| Comorbidity | 1 | 2010 | 2392 | 0.010 |
Why?
|
| Pyridines | 1 | 2010 | 1311 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2010 | 1857 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 3408 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 2388 | 0.010 |
Why?
|
| Prevalence | 1 | 2010 | 3401 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 3194 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 3108 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 5310 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2010 | 2450 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 7665 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 16205 | 0.010 |
Why?
|
| Texas | 1 | 2010 | 6447 | 0.010 |
Why?
|
| Mice | 2 | 1997 | 35594 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 4961 | 0.010 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 1998 | 38 | 0.010 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 1998 | 123 | 0.010 |
Why?
|
| Solubility | 1 | 1998 | 247 | 0.010 |
Why?
|
| Toxins, Biological | 1 | 1998 | 70 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 6768 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1995 | 6686 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1997 | 239 | 0.010 |
Why?
|
| Influenza A virus | 1 | 1998 | 166 | 0.010 |
Why?
|
| Dogs | 1 | 1998 | 1160 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 10706 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1997 | 475 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1997 | 929 | 0.010 |
Why?
|
| Muramic Acids | 1 | 1995 | 1 | 0.010 |
Why?
|
| Viral Proteins | 1 | 1998 | 491 | 0.010 |
Why?
|
| Cell Wall | 1 | 1995 | 51 | 0.010 |
Why?
|
| Infant | 1 | 2010 | 13985 | 0.010 |
Why?
|
| Neuroimmunomodulation | 1 | 1995 | 72 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1994 | 404 | 0.010 |
Why?
|
| Virus Replication | 1 | 1998 | 784 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1994 | 223 | 0.010 |
Why?
|
| Spleen | 1 | 1994 | 726 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1997 | 1825 | 0.010 |
Why?
|
| Sleep Wake Disorders | 1 | 1995 | 373 | 0.010 |
Why?
|
| Virus Diseases | 1 | 1995 | 392 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1995 | 508 | 0.010 |
Why?
|
| Cell Line | 1 | 1998 | 5339 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 3341 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 4569 | 0.000 |
Why?
|
| Base Sequence | 1 | 1994 | 5437 | 0.000 |
Why?
|
| Neurons | 1 | 1995 | 2454 | 0.000 |
Why?
|